WO2007042885A3 - Therapeutic combination comprising methotrexate and a specified inhibitor of mek1 and mek2 - Google Patents

Therapeutic combination comprising methotrexate and a specified inhibitor of mek1 and mek2 Download PDF

Info

Publication number
WO2007042885A3
WO2007042885A3 PCT/IB2006/002745 IB2006002745W WO2007042885A3 WO 2007042885 A3 WO2007042885 A3 WO 2007042885A3 IB 2006002745 W IB2006002745 W IB 2006002745W WO 2007042885 A3 WO2007042885 A3 WO 2007042885A3
Authority
WO
WIPO (PCT)
Prior art keywords
mek2
mek1
methotrexate
therapeutic combination
specified inhibitor
Prior art date
Application number
PCT/IB2006/002745
Other languages
French (fr)
Other versions
WO2007042885A2 (en
Inventor
Craig Mason Flory
Wayne Daniel Klohs
Mark Bradley Meyer
Bernhardt George Zeiher
Original Assignee
Pfizer Prod Inc
Craig Mason Flory
Wayne Daniel Klohs
Mark Bradley Meyer
Bernhardt George Zeiher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Craig Mason Flory, Wayne Daniel Klohs, Mark Bradley Meyer, Bernhardt George Zeiher filed Critical Pfizer Prod Inc
Publication of WO2007042885A2 publication Critical patent/WO2007042885A2/en
Publication of WO2007042885A3 publication Critical patent/WO2007042885A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention relates to a method of treating rheumatoid arthritis with a combination, consisting essentially of N-[4-[[(2,4-diamino-6- pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid, or a pharmaceutically acceptable salt thereof, and N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and related combinations and pharmaceutical compositions.
PCT/IB2006/002745 2005-10-07 2006-09-25 Therapeutic combination comprising methotrexate and a specified inhibitor of mek1 and mek2 WO2007042885A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72454205P 2005-10-07 2005-10-07
US60/724,542 2005-10-07

Publications (2)

Publication Number Publication Date
WO2007042885A2 WO2007042885A2 (en) 2007-04-19
WO2007042885A3 true WO2007042885A3 (en) 2007-12-06

Family

ID=37943172

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/002745 WO2007042885A2 (en) 2005-10-07 2006-09-25 Therapeutic combination comprising methotrexate and a specified inhibitor of mek1 and mek2

Country Status (3)

Country Link
JP (1) JP2007106762A (en)
AR (1) AR055677A1 (en)
WO (1) WO2007042885A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11084780B1 (en) 2021-02-17 2021-08-10 Springworks Therapeutics, Inc. Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11066358B1 (en) 2021-02-17 2021-07-20 Warner-Lambert Company Llc Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
US11571402B2 (en) 2021-02-17 2023-02-07 Springworks Therapeutics, Inc. Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
WO2023223205A1 (en) 2022-05-17 2023-11-23 Teva Pharmaceuticals International Gmbh Solid state forms of mirdametinib and process for preparation thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002006213A2 (en) * 2000-07-19 2002-01-24 Warner-Lambert Company Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
WO2005040098A1 (en) * 2003-10-21 2005-05-06 Warner-Lambert Company Llc Polymorphic form of n-[(r)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002006213A2 (en) * 2000-07-19 2002-01-24 Warner-Lambert Company Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
WO2005040098A1 (en) * 2003-10-21 2005-05-06 Warner-Lambert Company Llc Polymorphic form of n-[(r)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CRONSTEIN B N: "Low-dose methotrexate: A mainstay in the treatment of rheumatoid arthritis", PHARMACOLOGICAL REVIEWS, WILLIAMS AND WILKINS INC., BALTIMORE, MD,, US, vol. 57, no. 2, June 2005 (2005-06-01), pages 163 - 172, XP002408704, ISSN: 0031-6997 *
HOEKSTRA M ET AL: "Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis", ANNALS OF THE RHEUMATIC DISEASES, BRITISH MEDICAL ASSOCIATION, LONDON, GB, vol. 62, no. 5, May 2003 (2003-05-01), pages 423 - 426, XP002410166, ISSN: 0003-4967 *

Also Published As

Publication number Publication date
WO2007042885A2 (en) 2007-04-19
AR055677A1 (en) 2007-08-29
JP2007106762A (en) 2007-04-26

Similar Documents

Publication Publication Date Title
EP1818047A3 (en) Oral administration form for difficulty soluble basic active ingredients
WO2005016876A3 (en) Cyclic amine bace-1 inhibitors having a benzamide substituent
NL300650I2 (en) Olodaterol, its R-enantiomer, mixtures of isomers thereof, acid addition salts with pharmacologically acceptable acids thereof, as well as solvates and / or hydrates thereof, in particular Olodaterol and Olodaterol hydrochloride
EP1734041A3 (en) Platelet ADP receptor inhibitors
DK1602370T3 (en) Synergistic combinations comprising a renin inhibitor for cardiovascular disease
WO2005020899A3 (en) Substituted cycloalkyamine derivatives as modulators of chemokine receptor activity
CA2362499A1 (en) Combinations of formoterol and mometasone furoate for asthma
CA2429844A1 (en) Mch antagonists and their use in the treatment of obesity
RS50876B (en) Use of flibanserin in the treatment of sexual disorders
JP2005514441A5 (en)
WO2007042885A3 (en) Therapeutic combination comprising methotrexate and a specified inhibitor of mek1 and mek2
UY27991A1 (en) POBROLIDONA DOMO INHIBITORS DERIVATIVES OF MAOB
WO2006124609A3 (en) Methods and compositions for treating arg
JP2009518415A5 (en)
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
WO2004030611A3 (en) Non-nucleoside reverse transcriptase inhibitors
RS50534B (en) Intranasal formulation of rotigotine
EP1769797A3 (en) Methods and compositions using cetirizine in combination with leukotriene inhibitors for treating conditions responsive to leukotriene inhibition
ATE402175T1 (en) 4-OXO-1-(3-SUBSTITUTEDPHENYL)-1,4-DIHYDRO-1, - NAPHTHYRIDINE-3-CARBONIC ACID AMIDE ALSPHOSHODIESTERASE-4 INHIBITORS
MXPA06002722A (en) A pharmaceutical composition comprising a p2x7 receptor antagonist and a nonsteroidal anti inflammatory drug.
CA2451519A1 (en) Tablet comprising cetirizine and pseudoephedrine
WO2005011594A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
WO2005004915A3 (en) Compositions comprising meloxicam
BR0206819A (en) Use of il-18 inhibitors for treatment and / or prevention of heart disease.
WO2004071156A3 (en) Use of edible acid in fast-dispersing pharmaceutical solid dosage forms

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06808933

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06808933

Country of ref document: EP

Kind code of ref document: A2